Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA

Walleye Capital LLC acquired a new position in Savara Inc. (NASDAQ:SVRA) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 248,720 shares of the company’s stock, valued at approximately $1,532,000. Walleye Capital LLC owned approximately 0.12% of Savara as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in SVRA. Swedbank AB increased its stake in Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock worth $5,126,000 after acquiring an additional 300,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Savara by 96.5% during the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after acquiring an additional 320,572 shares during the last quarter. F m Investments LLC boosted its position in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after acquiring an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara during the fourth quarter worth about $10,182,000. Finally, Orbimed Advisors LLC purchased a new position in shares of Savara during the first quarter worth about $3,467,000. Institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Oppenheimer assumed coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.14.

Key Stories Impacting Savara

Here are the key news stories impacting Savara this week:

• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.62 from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter.
• Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of $0.37 from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years.
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook.
• Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization.

Savara Trading Up 2.1%

Shares of SVRA stock opened at $5.38 on Friday. The company has a quick ratio of 13.47, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average price of $5.65 and a two-hundred day moving average price of $5.48. Savara Inc. has a 12-month low of $2.92 and a 12-month high of $7.01. The firm has a market cap of $1.11 billion, a P/E ratio of -9.28 and a beta of 0.29.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Equities analysts anticipate that Savara Inc. will post -0.62 EPS for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.